Brain Tumors Clinical Trial
Official title:
Working Memory Performance Among Childhood Brain Tumor Survivors Treated With Conformal Radiation Therapy: A Pilot Study
Verified date | October 2011 |
Source | St. Jude Children's Research Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Children treated with radiation therapy for brain tumors are at risk for cognitive problems.
These problems have typically been demonstrated on global cognitive measures including
measures of intellectual functioning (IQ). Identification of specific areas of impairment
can assist in isolating vulnerable brain areas and developing targeted interventions.
In this study, we assess brain tumor survivors, solid tumor controls and healthy sibling
controls using measures of working memory (online maintenance and manipulation of
information) in order to identify a specific cognitive process that may underlie the
observed decline in IQ. We are also exploring relationships among working memory performance
with IQ, clinical characteristics and a specific genetic factor of interest.
Status | Completed |
Enrollment | 130 |
Est. completion date | December 2009 |
Est. primary completion date | December 2009 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 8 Years to 18 Years |
Eligibility |
Inclusion Criteria: Brain Tumor Patients - Treated for a primary central nervous system (CNS) tumor with conformal radiation therapy and enrolled on the institutional protocol RT-1 - Initiated radiation therapy at least 2 years prior to enrollment with no evidence of recurrent disease - Age 8-18 years inclusive at the time of enrollment, with sampling to obtain a broad cross-section of participants in terms of age, tumor location and time since RT initiation - English as the primary language - Research participant and one parent willing to participate and provide consent/assent according to institutional guidelines Solid Tumor Patient Controls - Treated for a solid tumor (i.e., Ewing's sarcoma, osteosarcoma, soft tissue/rhabdomyosarcoma, neuroblastoma or Wilms tumor) at St. Jude without CNS directed therapy - Diagnosed at least 2 years prior to enrollment - Age 8-18 inclusive at the time of enrollment, with age, gender and race sampling to broadly match the brain tumor group - English as the primary language - Research participant and one parent willing to participate and provide consent/assent according to institutional guidelines Sibling Controls - Healthy sibling controls- siblings of St. Jude patients treated for a brain tumor (not necessarily on RT-1) - Age 8-18 inclusive, with age and gender sampling to broadly match the patient group - English as a primary language - Research participant and one parent willing to participate and provide consent/assent according to institutional guidelines Exclusion Criteria: Brain Tumor Patients - Significant impairment in global intellectual functioning (operationalized as an estimated IQ less than 70 as indicated by most recent RT-1 testing) - History of documented CNS injury or disease predating cancer diagnosis - History of documented Attention Deficit Hyperactivity Disorder (ADHD) predating cancer diagnosis by at least one year (must have been diagnosed by a physician with medication prescribed) - Treatment with psychostimulant or psychotropic medication within two weeks of study enrollment - Sensory or motor impairment that would preclude valid cognitive testing Solid Tumor and Sibling Controls - Significant impairment in global intellectual functioning (operationalized as a history of special education in a self-contained classroom) - History of documented CNS injury or disease - History of documented Attention Deficit Hyperactivity Disorder (ADHD) (must have been diagnosed by a physician with medication prescribed) - Treatment with psychostimulant or psychotropic medication within two weeks of study enrollment - Sensory or motor impairment that would preclude valid cognitive testing |
Country | Name | City | State |
---|---|---|---|
United States | St. Jude Children's Research Hospital | Memphis | Tennessee |
Lead Sponsor | Collaborator |
---|---|
St. Jude Children's Research Hospital | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Performance on experimental working memory measures (computerized self-ordered pointing tasks) | Collected during one time cross-sectional assessment. | ||
Secondary | Abbreviated IQ (WASI), episodic memory measures (computerized word and face recognition tasks) and parent questionnaires of executive (BRIEF) and adaptive (ABAS-II) functioning. | Collected during one time cross-sectional assessment. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02846038 -
Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
|
||
Completed |
NCT02537106 -
A Comparison of the Effect of 1.5 Versus 3% NaCl on Brain Relaxation and Microcirculation
|
N/A | |
Completed |
NCT01951950 -
Nicardipine vs Esmolol Craniotomy Emergence
|
Phase 1 | |
Completed |
NCT01222780 -
To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer
|
Phase 1 | |
Completed |
NCT00873184 -
Study of Massage Therapy Within a Brain Tumor Setting
|
N/A | |
Active, not recruiting |
NCT01115777 -
Prospective Assessment of Quality of Life (QOL) in Pediatric Patients Treated With Radiation Therapy for Brain Tumors and Non-central Nervous System (Non-CNS) Malignancies
|
||
Completed |
NCT00724191 -
Evaluation of Human Brain Tumor Therapy Response by Magnetic Resonance (MR)
|
||
Completed |
NCT00003935 -
Combination Chemotherapy Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma
|
Phase 1 | |
Recruiting |
NCT04128306 -
Brain Areas of Time-To-Contact Perception: an Awake Surgery Study
|
N/A | |
Recruiting |
NCT05202899 -
Effect of Sugammadex for Reversal of Rocuronium-induced Neuromuscular Block on Perioperative Management of Awake Craniotomy
|
Phase 4 | |
Completed |
NCT00707343 -
[F-18] Fluorothymidine (FLT) Imaging on Patients With Primary Brain Tumors
|
Phase 1 | |
Completed |
NCT00850278 -
Assessment of [18F]FLT-PET Imaging for Diagnosis and Prognosis of Brain Tumors
|
N/A | |
Completed |
NCT00528437 -
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
|
Phase 2 | |
Terminated |
NCT00107471 -
Topotecan, G-CSF, and Radiation Therapy in Treating Young Patients With Newly Diagnosed Brain Stem Glioma
|
Phase 1/Phase 2 | |
Completed |
NCT00187174 -
Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors
|
Phase 1 | |
Completed |
NCT00135876 -
Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients
|
Phase 3 | |
Completed |
NCT00062478 -
Study of Karenitecin (BNP1350) in Patients With Brain Tumors
|
Phase 2 | |
Completed |
NCT00241670 -
Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid
|
Phase 3 | |
Not yet recruiting |
NCT01445691 -
More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery
|
Phase 2 | |
Terminated |
NCT01018290 -
Navigated Transcranial Magnetic Stimulation in Tumor Surgery
|
N/A |